Gene Therapy LentiGlobin Continues to Show Good Results, Bluebird Bio Says
News
Bluebird bio reported that its investigational gene therapy LentiGlobin showed promising results for severe sickle cell disease (SCD) patients in a Phase 1 clinical trial. Data from the ongoing HGB-206 Phase ... Read more